
Gynesonics
Founded Year
2005Stage
Series H | AliveTotal Raised
$328.37MLast Raised
$49.5M | 6 mos agoAbout Gynesonics
Gynesonics women's healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids. It develops the sonata system for the transcervical treatment of symptomatic uterine fibroids under intrauterine sonography guidance. The sonata system uses radiofrequency energy to ablate fibroids under intrauterine sonography guidance. Gynesonics was founded in 2005 and is based in Redwood City, California.
Gynesonics Patents
Gynesonics has filed 48 patents.
The 3 most popular patent topics include:
- Medical equipment
- Gynaecology
- Juniperus

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
10/28/2019 | 3/28/2023 | Medical ultrasonography, Medical equipment, Medical imaging, Medical physics, Cardiology | Grant |
Application Date | 10/28/2019 |
---|---|
Grant Date | 3/28/2023 |
Title | |
Related Topics | Medical ultrasonography, Medical equipment, Medical imaging, Medical physics, Cardiology |
Status | Grant |
Latest Gynesonics News
Aug 3, 2023
News provided by Share this article Share this article NEW YORK, Aug. 3, 2023 /PRNewswire/ -- The uterine fibroid treatment device market is expected to grow by USD 2,692.65 million from 2022 to 2027, according to Technavio. As per the latest report, the market will progress at a CAGR of 9.12% during the forecast period. Improving healthcare systems in emerging economies is an emerging uterine fibroid treatment device market trend. Underserved markets for healthcare products and services, including medical devices significantly represented in developing and emerging economies, such as Brazil, Russia, India, China, Saudi Arabia, and Mexico. Furthermore, even though emerging local companies in developing countries are making efforts toward creating innovative products with local materials at affordable prices, there is still a huge potential for established global companies in these developing markets. Hence, such trends boost the growth of the uterine fibroid treatment device market during the forecast period. View a Sample Report within minutes! Rest Of World (ROW) The invasive treatment segment will be significant during the forecast period. This segment includes surgical methods that involve invasive procedures to remove or destroy uterine fibroids and currently hold a significant share of the market. The significant market share is because many women continue to opt for surgical methods as the standard treatment for fibroids. Hysterectomy, myomectomy, and others are some of the major examples of invasive uterine fibroids treatment. Traditional surgical procedures provide an opportunity for physicians to accurately remove the fibroids with minimal risks compared with any other alternative treatments. Hence, such factors boost the invasive treatment segment of the uterine fibroid treatment device market during the forecast period. To learn more about the global trends impacting the future of market research, download a sample report! Uterine Fibroid Treatment Device Market 2023-2027: Market Dynamics An increase in healthcare expenditure drives the growth of the uterine fibroid treatment device market. In 2021, it was estimated that global healthcare expenditure was expected to grow by 5.8% and reach USD 8.8 trillion. Due to the increase in healthcare expenditure, the demand for medical devices will rise, which will increase the demand for uterine fibroid treatment devices. Furthermore, serving developing countries will require technological innovations as well as innovations in delivery and business models by healthcare companies. Hence, such factors boost the growth of the uterine fibroid treatment device market during the forecast period. The high cost of treatment of uterine fibroid challenges the growth of the uterine fibroid treatment device market. These devices and procedures can be expensive, and the high cost of treatment can be a significant barrier to the growth of the market. The cost of purchasing, maintaining, and upgrading these devices may also be prohibitive for some healthcare providers. This leads to delays in the adoption of new and innovative devices. Hence, such challenges impede the growth of the uterine fibroid treatment device market during the forecast period. What's New? - Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession Global competitiveness and key competitor positions Market presence across multiple geographical footprints - Strong/Active/Niche/Trivial - Buy the report! Uterine Fibroid Treatment Device Market 2023-2027: Vendor Analysis The market is concentrated, and the degree of concentration will accelerate during the forecast period. We provide a detailed analysis of around 25 vendors operating in the Uterine Fibroid Treatment Device Market, including some of the vendors such as Boston Scientific Corp., Conmed Corp., Gynesonics Inc., Hologic Inc., INSIGHTEC Ltd., KARL STORZ SE and Co. KG, Lumenis Be Ltd, Medtronic Plc, Merit Medical Systems Inc., Minerva Surgical Inc., Olympus Corp., and The Cooper Companies Inc. Backed with competitive intelligence and benchmarking, our research reports on the Uterine Fibroid Treatment Device Market are designed to provide entry support, customer profile, and M&As as well as go-to-market strategy support. Company Offerings Conmed Corp. - The company offers uterine fibroid treatment devices such as the AirSeal system. Gynesonics Inc. - The company offers uterine fibroid treatment devices such as Sonata System. Uterine Fibroid Treatment Device Market 2023-2027: Key Highlights CAGR of the market during the forecast period 2023-2027 Detailed information on factors that will assist uterine fibroid treatment device market growth during the next five years Estimation of the uterine fibroid treatment device market size and its contribution to the parent market Predictions on upcoming trends and changes in consumer behavior The growth of the uterine fibroid treatment device market Analysis of the market's competitive landscape and detailed information on vendors Comprehensive details of factors that will challenge the growth of uterine fibroid treatment device market vendors Gain instant access to 17,000+ market research reports. Related Reports: Based on Technavio's market sizing methodology, the gynecological cancers therapeutics market size is predicted to surge to USD 14.22 billion from 2021 to 2026 at a CAGR of 14.67%. This report further entails gynecological cancers therapeutics market segmentations, including Type - Uterine cancer, Ovarian cancer, cervical cancer, and others, and Geography - North America, Europe, Asia, and Rest of World (ROW). The increasing incidence of gynecological cancers is notably driving the gynecological cancers therapeutics market growth. The intrauterine contraceptive devices (IUD) market is estimated to grow at a CAGR of 3.98% between 2022 and 2027. The size of the market is forecast to increase by USD 965.49 million. The market has been segmented by Type (Hormonal intrauterine device and Copper intrauterine device), End-user (Hospitals, Gynecology clinics, and Others), and Geography (North America, Europe, APAC, and Rest of World (ROW)). The increasing number of unplanned pregnancies and unwanted abortions is notably driving the IUD market growth. Uterine Fibroid Treatment Device Market Scope Report Coverage Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Historic Market Size 4.1 Global uterine fibroid treatment device market 2017 - 2021 Exhibit 18: Historic Market Size – Data Table on global uterine fibroid treatment device market 2017 - 2021 ($ million) 4.2 Therapeutic Area Segment Analysis 2017 - 2021 Exhibit 19: Historic Market Size – Therapeutic Area Segment 2017 - 2021 ($ million) 4.3 Technology Segment Analysis 2017 - 2021 Exhibit 20: Historic Market Size – Technology Segment 2017 - 2021 ($ million) 4.4 Geography Segment Analysis 2017 - 2021 Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million) 4.5 Country Segment Analysis 2017 - 2021 Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million) 5 Five Forces Analysis 6 Market Segmentation by Therapeutic Area 6.1 Market segments Exhibit 31: Data Table on Therapeutic Area - Market share 2022-2027 (%) 6.2 Comparison by Therapeutic Area Exhibit 32: Chart on Comparison by Therapeutic Area Exhibit 33: Data Table on Comparison by Therapeutic Area 6.3 Invasive treatment - Market size and forecast 2022-2027 Exhibit 34: Chart on Invasive treatment - Market size and forecast 2022-2027 ($ million) Exhibit 35: Data Table on Invasive treatment - Market size and forecast 2022-2027 ($ million) Exhibit 36: Chart on Invasive treatment - Year-over-year growth 2022-2027 (%) Exhibit 37: Data Table on Invasive treatment - Year-over-year growth 2022-2027 (%) 6.4 Minimally invasive treatment - Market size and forecast 2022-2027 Exhibit 38: Chart on Minimally invasive treatment - Market size and forecast 2022-2027 ($ million) Exhibit 39: Data Table on Minimally invasive treatment - Market size and forecast 2022-2027 ($ million) Exhibit 40: Chart on Minimally invasive treatment - Year-over-year growth 2022-2027 (%) Exhibit 41: Data Table on Minimally invasive treatment - Year-over-year growth 2022-2027 (%) 6.5 Non-invasive treatment - Market size and forecast 2022-2027 Exhibit 42: Chart on Non-invasive treatment - Market size and forecast 2022-2027 ($ million) Exhibit 43: Data Table on Non-invasive treatment - Market size and forecast 2022-2027 ($ million) Exhibit 44: Chart on Non-invasive treatment - Year-over-year growth 2022-2027 (%) Exhibit 45: Data Table on Non-invasive treatment - Year-over-year growth 2022-2027 (%) 6.6 Market opportunity by Therapeutic Area Exhibit 46: Market opportunity by Therapeutic Area ($ million) Exhibit 47: Data Table on Market opportunity by Therapeutic Area ($ million) 7 Market Segmentation by Technology 7.1 Market segments Exhibit 51: Data Table on Comparison by Technology 7.3 Surgical techniques - Market size and forecast 2022-2027 Exhibit 52: Chart on Surgical techniques - Market size and forecast 2022-2027 ($ million) Exhibit 53: Data Table on Surgical techniques - Market size and forecast 2022-2027 ($ million) Exhibit 54: Chart on Surgical techniques - Year-over-year growth 2022-2027 (%) Exhibit 55: Data Table on Surgical techniques - Year-over-year growth 2022-2027 (%) 7.4 Laparoscopic techniques - Market size and forecast 2022-2027 Exhibit 56: Chart on Laparoscopic techniques - Market size and forecast 2022-2027 ($ million) Exhibit 57: Data Table on Laparoscopic techniques - Market size and forecast 2022-2027 ($ million) Exhibit 58: Chart on Laparoscopic techniques - Year-over-year growth 2022-2027 (%) Exhibit 59: Data Table on Laparoscopic techniques - Year-over-year growth 2022-2027 (%) 7.5 Ablation techniques - Market size and forecast 2022-2027 Exhibit 60: Chart on Ablation techniques - Market size and forecast 2022-2027 ($ million) Exhibit 61: Data Table on Ablation techniques - Market size and forecast 2022-2027 ($ million) Exhibit 62: Chart on Ablation techniques - Year-over-year growth 2022-2027 (%) Exhibit 63: Data Table on Ablation techniques - Year-over-year growth 2022-2027 (%) 7.6 Embolization techniques - Market size and forecast 2022-2027 Exhibit 64: Chart on Embolization techniques - Market size and forecast 2022-2027 ($ million) Exhibit 65: Data Table on Embolization techniques - Market size and forecast 2022-2027 ($ million) Exhibit 66: Chart on Embolization techniques - Year-over-year growth 2022-2027 (%) Exhibit 67: Data Table on Embolization techniques - Year-over-year growth 2022-2027 (%) 7.7 Market opportunity by Technology Exhibit 68: Market opportunity by Technology ($ million) Exhibit 69: Data Table on Market opportunity by Technology ($ million) 8 Customer Landscape Exhibit 74: Data Table on Geographic comparison 9.3 North America - Market size and forecast 2022-2027 Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%) 9.4 Europe - Market size and forecast 2022-2027 Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%) 9.5 Asia - Market size and forecast 2022-2027 Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%) 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) 9.7 US - Market size and forecast 2022-2027 Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%) Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%) 9.8 Japan - Market size and forecast 2022-2027 Exhibit 95: Chart on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 96: Data Table on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 97: Chart on Japan - Year-over-year growth 2022-2027 (%) Exhibit 98: Data Table on Japan - Year-over-year growth 2022-2027 (%) 9.9 Germany - Market size and forecast 2022-2027 Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%) 9.10 China - Market size and forecast 2022-2027 Exhibit 103: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibit 104: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibit 105: Chart on China - Year-over-year growth 2022-2027 (%) Exhibit 106: Data Table on China - Year-over-year growth 2022-2027 (%) 9.11 Canada - Market size and forecast 2022-2027 Exhibit 107: Chart on Canada - Market size and forecast 2022-2027 ($ million) Exhibit 108: Data Table on Canada - Market size and forecast 2022-2027 ($ million) Exhibit 109: Chart on Canada - Year-over-year growth 2022-2027 (%) Exhibit 110: Data Table on Canada - Year-over-year growth 2022-2027 (%) 9.12 Market opportunity by geography Exhibit 111: Market opportunity by geography ($ million) Exhibit 112: Data Tables on Market opportunity by geography ($ million) 10 Drivers, Challenges, and Trends 10.1 Market drivers About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact
Gynesonics Frequently Asked Questions (FAQ)
When was Gynesonics founded?
Gynesonics was founded in 2005.
Where is Gynesonics's headquarters?
Gynesonics's headquarters is located at 600 Chesapeake Drive, Redwood City.
What is Gynesonics's latest funding round?
Gynesonics's latest funding round is Series H.
How much did Gynesonics raise?
Gynesonics raised a total of $328.37M.
Who are the investors of Gynesonics?
Investors of Gynesonics include Advanced Technology Ventures, HBM Partners, Endeavour Vision, Bain Capital, Amzak Health and 11 more.
Who are Gynesonics's competitors?
Competitors of Gynesonics include Monteris Medical, Endologix, BioProtect, Aptus Endosystems, Interlace Medical and 12 more.
Compare Gynesonics to Competitors

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation, and is proven to resolve and restore normal mitral valve function. It was formerly known as mValve. The company was founded in 2007 and is based in St. Louis Park, Minnesota.

Ecochlor develops ballast water treatment systems that have been designed to safely and economically eliminate the worldwide transfer of aquatic invasive species and human pathogens such as cholera, in ship ballast water.
Intersect Partners is a California based medical devices company. The company primarily produces intragastric balloons, stent-like neurological medical devices, and associated minimally invasive drug delivery and device systems.
Ouroboros Medical is a medical devices for minimally invasive spinal fusion

Vertos Medical operates as a medical device company. It focuses on developing minimally invasive treatments for lumbar spinal stenosis (LSS). Its technologies include mild, which offers a guided therapeutic LSS treatment that requires no general anesthesia, no implants, and no stitches. The company was formerly known as X-Sten. It was founded in 2005 and is based in Aliso Viejo, California.